導(dǎo)師簡(jiǎn)介

姓名：劉云峰性別：女政治面貌：中共黨員學(xué)歷：研究生學(xué)位：博士職稱：主任醫(yī)師

博、碩導(dǎo)師：博士生導(dǎo)師本崗位工作年數(shù)：29

研究方向：內(nèi)分泌遺傳代謝學(xué)

榮譽(yù)稱號(hào)：

1.山西省學(xué)術(shù)技術(shù)帶頭人，

2.“三晉英才”拔尖骨干人才

3.山西省衛(wèi)健委“四個(gè)一批”科技興醫(yī)創(chuàng)新計(jì)劃項(xiàng)目醫(yī)學(xué)科技領(lǐng)軍人才

學(xué)術(shù)任職：

1.中國(guó)醫(yī)院協(xié)會(huì)罕見(jiàn)病專業(yè)委員會(huì)委員

2.山西省醫(yī)學(xué)會(huì)第十屆內(nèi)分泌專業(yè)委員會(huì)副主任委員

3.中國(guó)研究型醫(yī)院糖尿病專業(yè)委員會(huì)委員

4.中國(guó)老年醫(yī)學(xué)會(huì)內(nèi)分泌代謝分會(huì)委員

5.山西省醫(yī)師協(xié)會(huì)青春期健康與醫(yī)學(xué)專業(yè)委員會(huì)副主任委員

6.山西省醫(yī)師協(xié)會(huì)糖尿病專業(yè)委員會(huì)副主任委員

近五年承擔(dān)科研課題情況：

1.山西省衛(wèi)生健康委員會(huì)，四個(gè)一批科技興醫(yī)創(chuàng)新計(jì)劃項(xiàng)目，2323XM022，CISD1調(diào)控Hepcidin改善2型糖尿病鐵過(guò)載相關(guān)胰島素抵抗的機(jī)制研究。2023.9-2025.9，15萬(wàn)，主持。（Four“batches”innovation project of invigorating medical through science and technology of Shanxi province）

2.山西省科技廳，中央引導(dǎo)地方項(xiàng)目，YDZJSX20231A059，自由探索類基礎(chǔ)研究，基于GLP-1和PPARγ的“一藥雙靶”新型抗NASH藥物研究。2024.1-2026.12月，35萬(wàn)，主持。（the Shanxi Provincial Central Leading Local Science and Technology Development Fund Project）

3.國(guó)家自然科學(xué)基金面上項(xiàng)目，82073909，小分子化合物多西環(huán)素降糖作用關(guān)鍵靶點(diǎn)GLP-1受體的確定及其促胰島素分泌機(jī)制研究，2021.1-2024.12，55萬(wàn)，在研，主持

代表性論著及近五年的代表性論文（限10項(xiàng)以內(nèi)）：

(1)Xu M, Wei H, Lv D, Wei Y, Liu Z, Zhang Y*,Liu Y*. Trends and future predictions of chronic kidney disease due to diabetes mellitus type 2 attributable to dietary risks: insights based on GBD 2021 data. Front Nutr. 2025 Jan 13;11:1494383. doi: 10.3389/fnut.2024.1494383. PMID: 39872139; PMCID: PMC11769828.

(2)Xu M, Lv D, Wei H, Li Z, Jin S, Liu Q, Zhang Y*,Liu Y*. Effects of antidiabetic agents on lipid metabolism of skeletal muscle: A narrative review. Diabetes Obes Metab. 2025 Jan 14. doi: 10.1111/dom.16189. Epub ahead of print. PMID: 39807619.

(3)Li R, Wu B, Yang X, Liu B, Zhang J, Li M, Zhang Y, Qiao Y,Liu Y*. Semi-quantitative CT score reflecting the degree of pulmonary infection as a risk factor of hypokalemia in COVID-19 patients: a cross-sectional study. Front Med (Lausanne). 2024 Oct 21;11:1366545. doi: 10.3389/fmed.2024.1366545. PMID: 39497851; PMCID: PMC11533888.

(4)Wang R, Chen K, Liu S, Ren R, Hou H, Zeng Q, Zhang Y*,Liu Y*. Design, synthesis and biological evaluation of novel oxazole derivatives as potential hypoglycemic agents. Bioorg Med Chem. 2024 Nov 15;114:117961. doi: 10.1016/j.bmc.2024.117961. Epub 2024 Oct 18. PMID: 39437535.

(5)Zhang X, Shi X, Zhang X, Zhang Y, Yu S, Zhang Y*,Liu Y*. Repositioning fluphenazine as a cuproptosis-dependent anti-breast cancer drug candidate based on TCGA database. Biomed Pharmacother. 2024 Sep;178:117293. doi: 10.1016/j.biopha.2024.117293. Epub 2024 Aug 13. PMID: 39142251.

(6)Xu M, Hao J, Qi Y, Wu B, Li R, Yang X, Zhang Y*,Liu Y*. Causal effects of gut microbiota on diabetic neuropathy: a two-sample Mendelian randomization study. Front Endocrinol (Lausanne). 2024 Aug 2;15:1388927. doi: 10.3389/fendo.2024.1388927. PMID: 39157679; PMCID: PMC11329939.

(7)Li Z, Wei H, Li R, Wu B, Xu M, Yang X, Zhang Y,Liu Y*. The effects of antihypertensive drugs on glucose metabolism. Diabetes Obes Metab. 2024 Nov;26(11):4820-4829. doi: 10.1111/dom.15821. Epub 2024 Aug 14. PMID: 39140233.

(8)Zhao X, Zeng Q, Yu S, Zhu X, Bin Hu, Deng L, Zhang Y,Liu Y*. GLP-1R mediates idebenone-reduced blood glucose in mice. Biomed Pharmacother. 2024 Sep;178:117202. doi: 10.1016/j.biopha.2024.117202. Epub 2024 Jul 24. PMID: 39053424.

(9)Wu B, Li R, Hao J, Qi Y, Liu B, Wei H, Li Z, Zhang Y*,Liu Y*. CT semi-quantitative score used as risk factor for hyponatremia in patients with COVID-19: a cross-sectional study. Front Endocrinol (Lausanne). 2024 Jun 14;15:1342204. doi: 10.3389/fendo.2024.1342204. PMID: 38948513; PMCID: PMC11211362.

(10)Wang B, Zhu X, Yu S, Xue H, Deng L, Zhang Y, Zhang Y*,Liu Y*. Roflumilast ameliorates GAN diet-induced non-alcoholic fatty liver disease by reducing hepatic steatosis and fibrosis in ob/ob mice. Biochem Biophys Res Commun. 2024 Aug 30;722:150170. doi: 10.1016/j.bbrc.2024.150170. Epub 2024 May 23. PMID: 38797152.